These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 14662209)

  • 1. Predictors of difficulty when discontinuing postmenopausal hormone therapy.
    Grady D; Ettinger B; Tosteson AN; Pressman A; Macer JL
    Obstet Gynecol; 2003 Dec; 102(6):1233-9. PubMed ID: 14662209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of postmenopausal hormone therapy.
    Grady D; Sawaya GF
    Am J Med; 2005 Dec; 118 Suppl 12B():163-5. PubMed ID: 16414343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms?
    Haskell SG; Bean-Mayberry B; Gordon K
    Menopause; 2009; 16(3):494-9. PubMed ID: 19182695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptom experience after discontinuing use of estrogen plus progestin.
    Ockene JK; Barad DH; Cochrane BB; Larson JC; Gass M; Wassertheil-Smoller S; Manson JE; Barnabei VM; Lane DS; Brzyski RG; Rosal MC; Wylie-Rosett J; Hays J
    JAMA; 2005 Jul; 294(2):183-93. PubMed ID: 16014592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women.
    Trémollieres FA; Pouilles JM; Ribot C
    Osteoporos Int; 2001; 12(5):385-90. PubMed ID: 11444087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Women's use of hormone replacement therapy for relief of menopausal symptoms, for prevention of osteoporosis, and after hysterectomy.
    Griffiths F; Convery B
    Br J Gen Pract; 1995 Jul; 45(396):355-8. PubMed ID: 7612339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy.
    Ettinger B; Grady D; Tosteson AN; Pressman A; Macer JL
    Obstet Gynecol; 2003 Dec; 102(6):1225-32. PubMed ID: 14662208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. After the Women's Health Initiative: decision making and trust of women taking hormone therapy.
    Schonberg MA; Davis RB; Wee CC
    Womens Health Issues; 2005; 15(4):187-95. PubMed ID: 16051110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. After the Women's Health Initiative: Postmenopausal women's experiences with discontinuing estrogen replacement therapy.
    Haskell SG
    J Womens Health (Larchmt); 2004 May; 13(4):438-42. PubMed ID: 15186661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term hormone therapy for perimenopausal and postmenopausal women.
    Marjoribanks J; Farquhar C; Roberts H; Lethaby A
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004143. PubMed ID: 22786488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
    Gallagher JC; Fowler SE; Detter JR; Sherman SS
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone replacement therapy among Danish women aged 45-65 years: prevalence, determinants, and compliance.
    Oddens BJ; Boulet MJ
    Obstet Gynecol; 1997 Aug; 90(2):269-77. PubMed ID: 9241307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Cardiovascular Mortality Risk in Women Discontinuing Postmenopausal Hormone Therapy.
    Mikkola TS; Tuomikoski P; Lyytinen H; Korhonen P; Hoti F; Vattulainen P; Gissler M; Ylikorkala O
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4588-94. PubMed ID: 26414962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone replacement therapy in postmenopausal women: utilization of health care resources by new users.
    Thorp JM; Gavin NI; Ohsfeldt RL
    Am J Obstet Gynecol; 2001 Aug; 185(2):318-26. PubMed ID: 11518885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
    Anderson GL; Limacher M; Assaf AR; Bassford T; Beresford SA; Black H; Bonds D; Brunner R; Brzyski R; Caan B; Chlebowski R; Curb D; Gass M; Hays J; Heiss G; Hendrix S; Howard BV; Hsia J; Hubbell A; Jackson R; Johnson KC; Judd H; Kotchen JM; Kuller L; LaCroix AZ; Lane D; Langer RD; Lasser N; Lewis CE; Manson J; Margolis K; Ockene J; O'Sullivan MJ; Phillips L; Prentice RL; Ritenbaugh C; Robbins J; Rossouw JE; Sarto G; Stefanick ML; Van Horn L; Wactawski-Wende J; Wallace R; Wassertheil-Smoller S;
    JAMA; 2004 Apr; 291(14):1701-12. PubMed ID: 15082697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group.
    Michaëlsson K; Baron JA; Farahmand BY; Johnell O; Magnusson C; Persson PG; Persson I; Ljunghall S
    BMJ; 1998 Jun; 316(7148):1858-63. PubMed ID: 9632404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy.
    Ettinger B; Pressman A
    Am J Manag Care; 1999 Jun; 5(6):779-85. PubMed ID: 10538456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
    Greenspan SL; Emkey RD; Bone HG; Weiss SR; Bell NH; Downs RW; McKeever C; Miller SS; Davidson M; Bolognese MA; Mulloy AL; Heyden N; Wu M; Kaur A; Lombardi A
    Ann Intern Med; 2002 Dec; 137(11):875-83. PubMed ID: 12458987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menopausal hormone therapy in a health maintenance organization before and after women's health initiative hormone trials termination.
    Wegienka G; Havstad S; Kelsey JL
    J Womens Health (Larchmt); 2006 May; 15(4):369-78. PubMed ID: 16724885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study.
    Greendale GA; Espeland M; Slone S; Marcus R; Barrett-Connor E;
    Arch Intern Med; 2002 Mar; 162(6):665-72. PubMed ID: 11911720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.